Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 102518-79-6 Chemical Structure| 102518-79-6

Structure of (-)-Huperzine A
CAS No.: 102518-79-6

Chemical Structure| 102518-79-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Huperzine A is a naturally occurring sesquiterpene alkaloid AChE inhibitor.

Synonyms: Hup A; (-)-Selagine.; Selagine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (-)-Huperzine A

CAS No. :102518-79-6
Formula : C15H18N2O
M.W : 242.32
SMILES Code : O=C1C=CC([C@@](/C2=C/C)(N)CC(C)=C[C@@]2([H])C3)=C3N1
Synonyms :
Hup A; (-)-Selagine.; Selagine
MDL No. :MFCD01714949

Safety of (-)-Huperzine A

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300-H310-H315-H319-H330-H335
Precautionary Statements:P260-P264-P280-P284-P301+P310-P302+P350
Class:6.1
UN#:1544
Packing Group:

Isoform Comparison

Biological Activity

Target
  • AChE

    AChE (G4 form), Ki:7 nM

  • GluR

    AChE (G4 form), Ki:7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat cortical neurons 1 μM and 10 μM 24 h To evaluate the effects of HupA on iron overload-induced LIP level increase. Results showed that HupA significantly decreased the iron overload-induced LIP level increase. Acta Pharmacol Sin. 2016 Nov;37(11):1391-1400
Rat cortical neurons 1 μM and 10 μM 24 h To evaluate the effects of HupA on iron overload-induced ATP decrease. Results showed that HupA significantly ameliorated the iron overload-induced ATP decrease. Acta Pharmacol Sin. 2016 Nov;37(11):1391-1400
Rat cortical neurons 1 μM and 10 μM 24 h To evaluate the effects of HupA on iron overload-induced ROS formation. Results showed that HupA significantly inhibited the iron overload-induced increase in ROS. Acta Pharmacol Sin. 2016 Nov;37(11):1391-1400
Rat cortical neurons 1 μM and 10 μM 24 h To evaluate the protective effects of HupA against iron overload-induced neuronal damage. Results showed that HupA significantly attenuated the iron overload-induced decrease in neuronal cell viability and improved neuronal morphology. Acta Pharmacol Sin. 2016 Nov;37(11):1391-1400
SH-SY5Y cells 10 μM 24 h HupA significantly increased ADAM10 levels, decreased BACE1 levels, increased sAPPα and C83 fragments, and decreased sAPPβ and C99 fragments, indicating that HupA modulates APP processing by enhancing the nonamyloidogenic pathway. Neuropsychopharmacology. 2011 Apr;36(5):1073-89

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced obese mice and ob/ob mice Intragastric administration 0.1 mg/kg/day and 0.3 mg/kg/day Once daily for 3 months Hup A (0.1 mg/kg/day) improved both the abilities of object recognition and spatial memory in HFD-fed mice, but not in ob/ob mice. Furthermore, Hup A treatment significantly upregulated the insulin and phosphorylated Akt levels in the cortex of HFD-fed mice, but not ob/ob mice. In addition, Hup A (0.3 mg/kg/day) significantly decreased cortical β-secretase (BACE1) expression. Acta Pharmacol Sin. 2020 Feb;41(2):145-153
C57BL/6N mice Chronic intermittent hypoxia model Intraperitoneal injection 0.1 mg/kg/day Once daily for 21 days Huperzine A-Liposomes (HuA-LIP) significantly ameliorated cognitive dysfunction and neuronal damage in CIH mice, elevated T-SOD and GSH-Px abilities, decreased MDA content, reduced brain iron levels by downregulating TfR1, hepcidin, and FTL expression, and improved synaptic plasticity by activating the PKAα/Erk/CREB/BDNF signaling pathway and elevating MAP2, PSD95, and synaptophysin. Int J Nanomedicine. 2023 Feb 17;18:843-859
APP/PS1 double-transgenic mice Alzheimer's disease model Intranasal administration 167 and 500 μg/kg Once daily for 4 months HupA reduced Aβ burden and generation, enhanced nonamyloidogenic processing of APP by inhibiting GSK3α/β activity and enhancing β-catenin levels, suggesting its neuroprotective effects involve not only AChE inhibition and antioxidation but also modulation of the Wnt/β-catenin signaling pathway. Neuropsychopharmacology. 2011 Apr;36(5):1073-89

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01136551 Healthy|Bioavailability UNKNOWN 2025-04-11 Hadassah University Hospital, ... More >>Jerusalem, Israel Less <<
NCT01012830 Schizophrenia|Dementia PHASE4 UNKNOWN 2025-04-11 Veterans Affairs Nebraska West... More >>ern Iowa Health Care System, Omaha, Nebraska, 68105, United States Less <<
NCT00083590 Alzheimer Disease PHASE2 COMPLETED 2025-11-07 University of Alabama, Birming... More >>ham, Alabama, 35294, United States|Banner Alzheimer's Institute, Phoenix, Arizona, 85006, United States|University of California, Irvine, Irvine, California, 92697, United States|University of California, San Diego, Alzheimer's Disease Research Center, La Jolla, California, 92037, United States|University of Southern California, Los Angeles, California, 90033, United States|University of California, Davis, Sacramento, California, 95817, United States|Howard University School of Medicine, Washington, DC, District of Columbia, 20060, United States|Georgetown University Medical Center, Memory Disorders Program, Washington, District of Columbia, 20057, United States|MD Clinical, Fort Lauderdale, Florida, 33321, United States|Roskamp Institute Memory Clinic, Tampa, Florida, 33617, United States|University of South Florida, Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, 33617, United States|Premiere Research Institute, West Palm Beach, Florida, 33407, United States|Emory University, Atlanta, Georgia, 30329, United States|Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, 60612, United States|ICPS Group, Boston, Massachusetts, 02131, United States|University of Nevada School of Medicine, Las Vegas, Nevada, 89102, United States|Alzheimer's Research Corporation, Manchester, New Jersey, 08759, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, 08855, United States|Albany Medical Center, Albany, New York, 12208, United States|New York University Medical Center, New York, New York, 10016, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, 10962, United States|University of Rochester Medical Center, Rochester, New York, 14620, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Oregon Health and Science University, Portland, Oregon, 97201, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Medical University of South Carolina, North Charleston, South Carolina, 29406, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Vermont College of Medicine, Burlington, Vermont, 05401, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.63mL

4.13mL

2.06mL

41.27mL

8.25mL

4.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories